Glaukos Corp (GKOS) 2022 Q2 法說會逐字稿

Welcome to Glaukos Corporation's Second Quarter 2022 Financial Results Conference Call. Copies of the company's press release and quarterly summary document, both issued after the market closed today, are available at www.glaukos.com. (Operator Instructions) This call is being recorded, and an archived replay will be available online in the Investor Relations section at www.glaukos.com.

I will now turn the call over to Chris Lewis, Vice President of Investor Relations and Corporate Affairs. Please go ahead.

Thank you, and good afternoon. Joining me today are Glaukos Chairman and CEO, Tom Burns; President and COO, Joe Gilliam; and CFO, Alex Thurman.

Similar to the last quarter, the company has posted a document on its Investor Relations website under the Financials & Filings Quarterly Results section titled Quarterly Summary. This document is designed to provide the investment community with a summarized and easily accessible reference document that details the key facts associated with the quarter, the state of the company's business objectives and strategies, and any forward statements or guidance we may make. This document has been and will continue to be provided alongside the company's earnings press release and is designed to be read by investors before the regularly scheduled quarterly conference call. As such, for this call, we will make brief prepared remarks and quickly transition into the question-and-answer session. It is our goal that this recently adopted format will make our quarterly earnings process more efficient and impactful for the investment community going forward. (Operator Instructions)

Please note that all statements other than statements of historical facts made on this call that address activities, events or developments we expect, believe, or anticipate will or may occur in the future are forward-looking statements. These include statements about our plans, objectives, strategies and prospects regarding, among other things, our sales, products, pipeline technologies, U.S. and international commercialization, integration and market development efforts, efficacy of our current and future products, competitive market position, regulatory strategies and reimbursement for our products, financial condition and results of operations as well as the expected impact of the COVID-19 pandemic on our business and operations. These statements are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Therefore, they may cause our actual results to differ materially from those expressed or implied by forward-looking statements. Review today's press release and our recent SEC filings for more information about these risk factors. You'll find these documents in the Investors section of our website at www.glaukos.com.

Finally, please note that during today's call we will also discuss certain non-GAAP financial measures, including results on an adjusted basis. We believe these financial measures can facilitate a more complete analysis and greater transparency into our ongoing results of operations, particularly when comparing underlying results from period to period. Please refer to the tables in our earnings press release available in the Investor Relations section of our website for a reconciliation of these measures to their most directly comparable GAAP financial measure.

With that, I will turn the call over to Glaukos Chairman and CEO, Tom Burns.

Thank you, Chris. Good afternoon, and thanks to everyone for joining us today. Today, Glaukos reported second quarter net sales of approximately $72.7 million, down 5% year-over-year on a constant currency basis, but up 9% sequentially versus the first quarter on a constant currency basis. As a reminder, the second quarter represents a challenging year-over-year comparable for many in the med tech industry, but in particular, for Glaukos. We are raising our 2022 net sales guidance range to $275 million to $280 million versus $270 million to $275 million previously, given our solid execution globally, better-than-expected second quarter results and latest forward outlook.

From a commercial perspective, we continue to be pleased with the execution of our strategies and the resiliency of our U.S. combo-cataract franchise in the face of the reimbursement headwinds thus far in 2022, with our glaucoma -- U.S. glaucoma franchise delivering strong sequential growth of 13%. During the latter part of the first quarter, we launched our iAccess device, a novel instrument with features that allow customers to perform goniotomy procedures. Surgeon adoption and utilization of iAccess continues to grow and market feedback remains positive.

During the latter part of the second quarter, we also commenced initial commercial launch activities for iPrime, our innovative new viscoelastic delivery device. While we remain in the very early stages of iPrime's controlled launch, this platform adds to our expanding portfolio of unique solutions designed to grow and improve treatment options for our surgeon customers and patients.

Our international glaucoma franchise once again delivered quarterly record sales despite significant foreign exchange headwinds as we execute our strategies to drive deeper penetration and broader adoption of MIGS around the globe. And within our Corneal Health franchise, we continue to focus on access for keratoconus patients suffering from this rare disease. We're investing in additional commercial payer market access coverage in response to sporadic issues that have emerged in 2022.

On the development front, we continue to advance our pipeline. Following the recent clearances and commercial launches of iAccess and iPrime, we're delighted to announce today that we have received FDA 510(k) clearance for iStent infinite, our novel 3-stent injectable system designed to provide foundational 24/7 IOP control for glaucoma patients. This FDA clearance represents a significant milestone for Glaukos and the MIGS market as the first ever microinvasive implantable device indicated for use as a stand-alone glaucoma treatment. Supported by strong pivotal data highlighting favorable safety and effectiveness, we believe iStent infinite may provide ophthalmic surgeons with a compelling new treatment alternative in a stand-alone procedure for patients with open-angle glaucoma uncontrolled by prior surgical and medical therapy. We are preparing to commence initial commercial launch activities for this promising technology later this year.

Our clinical and regulatory teams also remain hard at work advancing pre-submission activities for iDose TR and Epioxa, respectively, and we expect to be in a position to announce top line Phase III data for iDose TR later this year. In terms of our earlier stage pipeline, we are happy to announce we completed patient enrollment in our iLution Phase II clinical trial for dry eye disease during the second quarter. We also expect to complete patient enrollment for our iLution Phase II clinical trial for presbyopia during this third quarter, and we anticipate initial data readouts for each of these trials by early 2023.

We are now in the midst of several new product launches and are planning for a robust cadence of new dropless platform and product introductions over the coming years that have the potential to fundamentally transform Glaukos over time and meaningfully advance the standard of care and improve outcomes for patients suffering from sight-threatening diseases. As such, we are continuing to invest in Glaukos to scale our team and to advance our mission to transform vision. We are excited about our prospects and confident in our ability to execute our plans in the years to come.

So with that, I'll open the call to questions. Operator?

(Operator Instructions) And we'll take our first question from Andrew Brackmann at William Blair.

Maybe just to start here on iDose. I appreciate all the commentary that you provided in your short remarks, Tom. But I guess as we sort of sit here mid-September, 13 months after the last patient enrolled that last arm of the trial, can you just sort of level set us on how you're thinking about that pipeline opportunity and your confidence level that it will be successful?

And I guess as a follow-up there, can you just talk about the scorecard that you're going to be looking at to evaluate the success beyond the top line data? Anything in particular that you'll be looking at in the study?

Yes, happy to take the question. So it's important to review just how successful this product has been. If we look and kind of scrutinize what happened in the Phase IIb data results that we recently announced earlier this year, we found that 70% of patients were well controlled on iDose with the same or fewer topical IOP-lowering meds in 36 months. And many of these patients were on 2 or 3 meds at pre-screening. The average -- the mean IOP reduction at 36 months for the iDose group in these various scenarios ranged from 8.3 to 8.5 millimeters of mercury, so really sustained reductions in intraocular pressure. So we were invariably pleased that -- and by any analysis, the iDose TR performed similarly to timolol 36 months in terms of the IOP reductions, but with far fewer topical medications versus timolol. So those were the kind of the top line efficacy results.

I think it's important, too, to then say, okay, well, what happened on the safety side? And the product was extremely well tolerated. We found no ocular hyperemia. We found no periorbital fat atrophy. And importantly, we saw really no clinically significant corneal endothelial cell loss versus timolol control and only one instance of hyperchromia or iris color change. And so these are significantly powerful safety factors for this device.

And so when we look at what the appetite that's occurring in the marketplace, there has always been a substantial kind of an underlying appetite for a sustained-release medication that could provide 24/7 control of glaucoma because noncompliance is so ubiquitous and such a rapid cause of the underlying progression of glaucoma disease. I think this product represents an incredibly different paradigm change to be able to treat. It's kind of a simple injection as a stand-alone procedure. I expect that it will be used to be able to overcome issues of noncompliance in glaucoma, issues of allergy with the disease state, issues of patients who have underlying ocular surface disease so you don't have to continue to pour topical agents that have toxic preservatives in the formulation on the surface of the eye. There are a number of different places that we think this product will be used, and not -- and importantly, we do believe that the use of iDose could become kind of a nice complementary product for the use in combination cataract for those patients who have comorbid glaucoma. So it's exciting.

I think you already see what's happened with Allergan. They've introduced their DURYSTA product. You can see the strong appetite and the uptake of that product. And the product is a novel, innovative product, but it does have some flaws. And as we know that one of the conditions of the label was it was restricted to a onetime use due to the relatively high rates of corneal endothelial cell loss. I'm hopeful and do not expect to see that because we tracked the corneal endothelial cell loss in iDose for 2 years as part of the Phase IIb clinical trial. And again, we saw no clinically significant corneal endothelial cell loss.

In addition, we're doing a cohort of patients that will look at exchanging the iDose in situ as part of the -- once they've implanted the product as part of the -- or the clinical trial. And we're following a cohort of patients, and we expect that data to be prepared and submitted as part of our NDA, which, if favorable, will give us the right to be able to exchange and move forward and use this product sequentially over a far longer period of time once the initial product has been depleted of medication.

So many of you have started to do your channel checks. You're finding a strong appetite. You're finding the excitement in the ranks. We expect to be able to enter with that tailwind behind us. I think Allergan, as a good marketer, has done and set a good predicate for us introducing their DURYSTA product, which lasts -- primarily designed to last 4 months in the eye. And it reached over $2,000 J-code ASP. When I see that, that gives me a strong backbone for introducing this product at a fair and productive rate for the business.

So we're excited. I think the important thing you heard in my opening comments is given direction from the beginning that we would publish data either by year-end or by early next year, and I'm moving that up to by year-end. And hopeful to get this data in the hands of investors and analysts in a very short period of time.

Very, very helpful. Maybe if I could just switch to iStent infinite quickly. Congrats on the approval there. What can you tell us about some of the initial sort of commercialization efforts and market-building efforts that you'll be putting out there? And how should we be thinking about uptake later this year and into '23 in light of that proposed facility rate for 2023?

Sure. Andrew, it's Joe. I'm happy to cover that. Obviously, we're excited about receiving the FDA clearance. As Tom mentioned, another chance for us to pioneer the market with the first ever microinvasive implantable device for stand-alone glaucoma treatment. So we're enthusiastic here about that launch. As it relates to timing, any time you receive an approval, you have a series of steps to finalize labels and sterile-approved inventory and training logistics in the formal launch plan. So we've been hard at work for the better part of a year preparing for this moment. I would expect that, for all intents and purposes, you'll see soft launch activities as we kind of exit the third quarter and head into the fourth. So that should give you a sense of that timing. You referenced, obviously, the facility fee and some of the proposed rules there. And I think on that, I'll just say that while we have work to do, we've been here before, and we're already hard at work on that front.

We'll move next to Chris Cooley at Stephens.

Congrats on a great quarter. Just two for me, if I may. First, just as a follow-up to Andrew's questions. Tom, I appreciate all the color you provided on iDose, but I was hoping you could maybe get a little bit more granular on the reimbursement outlook and the pathway there. Obviously, DURYSTA provides a predicate in the early stages, but you would think would have a longer duration of effect when we think about iDose TR. Could you just kind of walk through that pathway for us and what you think we could possibly envision when we think about reimbursement for the device?

And then secondly, just thinking again, you're looking at this deck, which, again, I'll have to commend Chris for it. It's a great piece of work. But as we look at that pipeline, increasingly, this looks like a pharmaceutical company, much like did Allergan. And so I'm just kind of curious about the next level of investment that you foresee the investor take. You've already obviously built out the bench from an R&D perspective. But what do you start to need to bring on board from a sales and marketing reimbursement kind of clin/dev-type aspect? And when does that start to kick into the P&L?

Yes, Chris, I'll be happy to take your questions. So the first question that you talked to me about was iDose reimbursement. So as you know, we've already, I think, set the table by applying for a Category 3 code with the AMA CPT Committee. We're successful in getting that code established. That code then, right now, it's under a current exclusion, so it doesn't be corrupted by people that would put data in that category in the hospital. And so what we'll do is we'll open it up with CMS just prior to commercial launch. And so what we'll do, much like we do with iStent infinite, is we'll have to establish and have a different MACs crosswalk, the perioperative procedure of putting in a stand-alone device of iDose and cross-lock that to a like Category 1 product to try to establish the highest professional fee. So it's something that we've been quite proficient at in the past, and we will continue to do so as we move forward with the iDose.

In terms of looking forward for payments in the APC level and in the -- with the device, this will be assigned an APC at the time of approval. Now remember, when we have -- this will be assigned a J-code. And so the J-code will be a carve-out for iDose itself. That product and that J-code, we'll take forward in the following way. We'll apply for a miscellaneous J-code at launch. We'll get that J-code, that miscellaneous code, and then HIX EX committees meet every quarter. And so then we'll look at formalizing and getting a formal J-code at the price point that we believe best serves the marketplace subsequent to launch.

The APC assignment will be much like it happens with iStent or iStent infinite. We'll get an assignment. We'll see if we like it, whether or not we need to reengage with CMS or if we sit tight. And remember, that APC assignment will be then wholly owned by the facility because the iDose will be carved out from that, so it puts the facility in a nice position of able to achieve profitability for doing these devices. So that's a look -- I think I've answered your question fully both on the professional fee side and on the facility side for iDose.

Again, DURYSTA has been set at a rate of about $2,000, designed to last for 4 months. I don't want to give any indication that we will price proportionately based upon length of therapy. But you can see that I have a lot of open field running in being able to establish a price point for iDose, which by the Phase IIb data appears to be lasting many months.

And so to your second question, you were talking about the pharmaceutical business. I think you need to bifurcate this and the approach in really 2 sections. One, surgical pharmaceuticals. And by those, I would list iDose, iDose TREX, iRock if we're successful bringing that forward, products like cross-linking, which really are a surgical pharmaceutical. And these are buy-and-build pharmaceuticals that can be handled and established by our current sales force, and this is where we really reap the reward of investing in our sales force and using it to scale by adding additional products, both devices and surgical pharmaceuticals.

When we get into the retail side of the pharmaceutical business, you know that's a very different animal. So when we look at topical applications of transdermal approaches like our iLution, which would go through pharmacy and wholesale channels, that's where we need to establish a secondary sales force to be able to approach and market those products. We've had substantial experience in the past in doing so. And make no mistake, we are confident we will establish the best teams and launch much like we have on the surgical device and pharmaceutical side, but we will need to bifurcate and have separate sales forces to do that. I think that answers your question.

We'll move next to Larry Biegelsen at Wells Fargo.

This is Charles on for Larry. Just a couple on iPrime. First, I've got to ask about -- it looks like (inaudible) you didn't get the device intensive in the rule there. Do you think that's possible that could change in the final rule? And then second, maybe just if you could talk a little bit about how long you might think that the initial controlled launch from iPrime might last.

Sure, Charles. This is Joe. I think like most things on reimbursement, we'd hesitate to speculate. It's clearly on the table up and through from the proposed rule through to the final rule. So entirely possible that, that could happen as a part of 66174. I think as it relates to the launch, as we mentioned, we've commenced the initial very early commercial launch activities in the quarter with our customers. And we're going to continue down that path. I don't think typically in these situations there is a single moment in time where it changes dramatically. It continues to sort of expand one wave at a time until we feel like our customers are proficient with this new option.

We'll go next to Ryan Zimmerman of BTIG.

Congrats on the quarter, guys. Tom, I want to ask you a couple of questions, and maybe this one is more for Joe, but I also have some high-level questions. So first, on guidance. I think about what you've done this year thus far, kind of about 50-plus percent or so for the first half of the year. And when we look at guidance that you raised $5 million at the midpoint, but if you go back to 2019 and the seasonality that we've seen, particularly in the fourth quarter, it suggests a similar run rate as what we saw in the first half of the year in terms of your guidance. And so why doesn't stick out a little bit higher for the remainder of the year, particularly in the fourth quarter, just given where you have guidance today. Hopefully, that was clear, Joe.

No, it is, Ryan. I think a totally fair question and one certainly that would anticipate given the analytics that you just, I think, articulated well. If you -- maybe first and foremost, I'm not so sure that in the situation with all the various things going on in the marketplace, product launch, otherwise, that I would look at the typical seasonality pattern and say that is a good guidepost or guideline for how to think about our year.

In particular -- and while I certainly follow the math, I think some things you have to think about in the second half as we evolve here, foreign exchange has certainly emerged as a pretty material headwind not just for us, I think, for everyone. So -- and you think about how that transpired over the course of the first quarter and then really strengthens the headwind in the second quarter and certainly at the end of the second quarter, entering into the third, you have to factor that in when you're trying to think about these things.

The second thing I would say that when you think about second half versus first half is that you've heard us say many times, we think -- we have a ton of respect for Alcon. We think they're a formidable competitor. And we expect that they'll continue to get their sea legs as the year progresses, both here in the U.S., but also internationally. So beyond that, the factors, the things that you've heard us talk about before, right, the ongoing impact of the CMS pro fee cuts, account staffing, types of things you probably heard from other companies as a part of this earnings season, some of the commercial payer volatility dynamics in the corneal health side, you kind of put all that together, and I guess the way we look at this coming into the call here is that we're pretty pleased to be able to raise the full year guidance again, right, and to be able to pass through really the entirety and a little bit more of the beat we just had in the second quarter, given sort of all that macroeconomic and specific headwinds that we face.

That was totally fair, Joe. I appreciate the commentary. And then, Tom, for you, I mean we've seen so much reimbursement change in the space, right? I mean the start of this year with codes around stent-based treatments, to now the proposed fees for canal-based devices. And I really would just appreciate your view of where reimbursement -- where the reimbursement landscape shakes out, how you think about the impact of all these moving components and Glaukos' philosophy given the multitude of devices that you now offer, how you navigate that in such a landscape that is in flux.

Well, it's a good question, Ryan, and it's something that I can assure you I think about almost daily. As we look at the shifting winds, a couple of things that are important is that some of the kind of transitions passed, right? So now we've moved into a Category 1 procedural code with combination cataract procedures. We know now where we stand. We were really pleased. We were able to carve back what were some significant draconian cuts that happened last year. And we fought hard and I think valiantly, and were able to really claw back, particularly on the APC side and be able to preserve really a fundamentally profitable procedure for the providers to be able to use the iStent device. And so that's really important.

Whenever you create new markets, we have to go through these growing pains with these new codes. And so we'll do so with iStent infinite within the next 6 to 9 months, clearly going into each of the MACs and be able to try to convince them to crosswalk this over to a light procedure that we feel appropriately represents the RVUs for the procedure. It's something that we believe we're good at, but it's something that takes a lot of time and muscle and patience. And there will be episodic setbacks in the process of doing this, much like there had been as we built the MIGS marketplace.

We'll see the same thing with iDose on the professional fee side. Although I think that once we settle on a iStent infinite, I expect that to be more streamlined and efficient moving forward. But that will be kind of a sideshow to the approach that we take with getting the J-code for the device. The J-code really is subject to our own procedural pharmacoeconomics with what we think is a fair and -- position on pricing in the marketplace where we think we can favorably represent and stand behind. And once we do present that, we will then get that through HIX EX and get a formal J-code that's not subject to review.

I want to remind everybody as well, with the TREX product that follows, because the TREX has substantially more API on board, approximately twice the amount, the way that CMS works is they will pay by basically the microgram of the product that's resident in the can itself of the iDose device. So that gives us legs as we move forward on payments and, I would say, consistency and predictability for investors as they think about that going forward.

So this is something that when you build new marketplaces, these are the growing pains that you go through and that you take. We're a leader. We're the pioneer. We're at the front end. We are creating this marketplace. We'll create a sustained marketplace for iDose therapy. We're creating a new marketplace in keratoconus with cross-linking and at subsequent generations. We've become good at it. It's a difficult process, but we're at it every day. And we think the payoff is there, and we're already seeing the payoff as we build value in this marketplace.

We'll move next to Matt O'Brien at Piper Sandler.

This is [Phil] on for Matt. Can you hear me all right?

Yes.

Yes, [Phil], we can hear you.

Congrats on the quarter. So my first one, on the dual procedure reimbursement dynamics, what are you seeing in terms of that staying power? More specifically, the Palmetto LCD recently came out with language surrounding goniotomy, stating that 65820 should not be used in conjunction with other angle surgery stents implants, even if the incision is minimal or incidental. So like kind of what's the staying power here of that dynamic going forward?

Thanks for the question, [Phil]. I think the -- first of all, it's an LCA, not LCD, technical difference, but it's important. I think anytime you have 2 separate devices, 2 separate company procedures and 2 distinct codes, surgeon discretion on what they deem medically reasonable and necessary should ultimately govern. I think that's the way most medicine is practiced and reimbursed throughout, not just in ophthalmology. I think on this one, the AAO has assessed this quite thoroughly given the growing trend that for years has been expanding here. I mean it's ultimately a sight-threatening progressive disease, where surgeons want to utilize multiple tools to optimize the clinical outcome for the patient. So AAO's looked at this. They've come out, both in March of 2022 with their bulletins around the utilization of canaloplasty in combination with extensive cataracts, and then more recently with the goniotomy fact sheet that we think is quite clear. So ultimately, our goal here is to provide surgeons with the best tools, right, that are minimally invasive to maximize the benefit to patients and hopefully grow the overall market while doing so. And as we navigate that, we'll continue to sort of work through things that pop up, whether it's Palmetto or other areas and on behalf of our customers and patients.

Great. And just a quick follow-up here. I assume some competitive trialing went on in the first half as surgeons became more aware of reimbursement changes and things of that nature. What are you seeing on that front? Others leave Glaukos and then some come back after trialing other products?

Well, I think anytime you have something the like of the changes that we saw in the CMS professional fees coming into the year, you're going to have some disruption in market trends. And I'd say sort of all of the above, right? You see customers who will try and trial other alternatives and come back, recognizing that stent-based solutions provide the best long-term therapy for their patients. And you also see the same type of try and trialing as we launch our own products -- new products into the marketplace. So I think we're well positioned. We've got a full portfolio of solutions for those physicians who want to try their alternatives for their patients, and we'll continue to navigate those dynamics as we move forward.

Awesome. Congrats again on the quarter.

We'll take our next question from Tom Stephan at Stifel.

If I can start on iDose, sorry if I missed this, but has the year-end '22 NDA submission target changed at all? I think the commentary in the press release was altered a bit. And I guess if so, is there something specific informing that change that you can call out? Just want to clarify the path forward.

And then second, on iDose, can you just talk a bit about site of service? I guess how should we think about whether or not this can move potentially beyond the OR?

Yes. Okay, Tom, I'll be happy to take the latter question first. And as we said all along, the iDose device today is a highly benign procedure that goes through a very, very small incision. And so one of the things we've been actively approaching and working on for some time is being able to come up with an applicator that can be able to go through potentially a small enough incision where you can keep the pressure in the eye and be able to not have what's called dehiscence where the aqueous will flow out of the eye and you're able to complete the iDose implantation with just a single injectable procedure. And if we are able to be able to execute and have that happen and we're making substantial progress in IDC, the fact that this can be able to move, and it's been our strategy from the beginning, to offer a product that can be used either in the ASC or eventually in a minor in-office suite. And I think we'll be able to get there with the iDose product.

When we do so, we'll have a couple of codes. We'll have codes in place that taper the iDose device in the ASC, which I've described previously. And we'll also have another code that will provide for the use of the iDose in office. So to the extent that we are successful in creating this applicator, and again, it's been our mission from the beginning, we'll be able to provide that.

Now having said that, right now, I'm agnostic about where this product is used. There are many surgeons that are telling me they want to stay and keep this in the ASC moving forward. And so it's my hope my delivery would be to be able to provide both options for surgeons over time.

Tom, it's Joe. On the first part of your question, I don't think there was anything intended to be in our IR materials press release or otherwise that would have made news with respect to the timing of an iDose submission. We've been talking around year-end for a while. I think actually the only thing that we said was the pre-submission activities are ongoing, which you'd expect. And probably the only news that -- in Tom's prepared remarks that we referenced was that he's prepared to provide the iDose data prior to year-end, which was a little bit moved forward from some of the prior guidance that we've given.

Got it. So just kind of blocking and tackling in terms of the pre-submission items for iDose, nothing specific to call out?

No.

I would say that. And further, Tom, if you take anything from my remarks, the fact that I've moved up from saying that we would have this by early next year and publish the data, again, we state that we'll be able to publish this data before that, and I want to be able to publish it before the end of the year. So again, I think that should show you things are on track. And as investors' appetites have been whetted for some time, we plan to deliver that data.

Perfect. That's helpful. And then my second question, just on U.S. glaucoma, I mean you beat our estimates handily. What surprised you most to the upside? Because I think, clearly, things are going well year-to-date. I guess what I'm trying to get at, are -- would you say the worst might be behind us in terms of the pressure points? And maybe you've now entered a point where things are kind of hitting a steady state or maybe even improvement? Hopefully, that makes sense.

It does, Tom. I think -- we're halfway through the year. I think we've been pleased with the resiliency and the stability of the core combo-cataract stent franchise. In the second quarter, we were pleased with what I'll still characterize as early contribution from iAccess and, overall, the continued stability in the pricing environment. I think to the core of your question, I think we've had 2 pretty good data points this year in Q1 and Q2 around what life can look like after the pro fee cuts. But I think it's a little bit early to sort of extrapolate that into victory in terms of how this will continue to transpire. And every day is a day that we're out there making sure that patients and surgeons are aware of the benefits of our products and making sure that we maximize the opportunity there.

We'll move next to Zach Weiner at Jefferies.

I just wanted to touch a little bit on that last question. Can you talk about some of the inflationary pressures and surgical throughput that you've seen through the quarter? And then if you're seeing any challenges from staffing as well?

Yes. I mean I think that we're not immune to what you've probably heard from multiple companies over the course of this earnings season. I think a combination of dynamics, some inflation, some related to COVID, some related to the job market shifts that have happened is clearly causing disruption in the labor market and in staffing for hospital administration, hospital techs, the support that help make these ORs and ASCs run at optimal efficiency. And we hear often from our customers over the course of this year, including recently around challenges they're having in maintaining that staffing, maintaining those OR lanes running at max capacity. So I think it is a dynamic that persists across the health care landscape and certainly within ophthalmology as well.

And we'll go next to Allen Gong at JPMorgan.

This is Rohin, actually, on for Allen. I just had a question about kind of your expectations for OpEx going forward. You have some pretty healthy step-ups in SG&A and R&D in the quarter. So how do you think we should think about spend kind of into the end of this year? And obviously, you're not -- obviously not providing formal guidance, but on 2023 as well, especially kind of what's needed for infinite and ultimately iDose?

Yes, Rohin, thanks for the question. This is Alex. I'll try to address that. So we did report it in our financials $90 million, $91 million. And as you know, included in that number is $10 million related to this license agreement that we did in the second quarter. So we're going to -- the things we'll talk about now, let's just take that $10 million out so that we're sitting at about a $80 million spend in Q2.

If you think about where we've come from this year, the first half, we put up about $150 million. And in previous quarters, we've talked about our profile being around a $300 million or north of $300 million OpEx company. And if you just think about that, what will happen in the next couple of quarters, it's probably about the same as we saw in Q2, maybe a little step-up, so that your OpEx -- or our OpEx for the year is probably in the $310 million range, maybe give or take a few million here or there.

The reasons for that are what might be what you expect, right? We have strategic investments in our R&D programs, clinical regulatory activities that are ongoing with our pipeline, and what we're doing as well as on the commercial side, we're continuing to enhance that organization. We've got new product launch activities happening and things of that nature.

And that does conclude our question-and-answer session for today. At this time, I'll turn the conference back over to management for any closing remarks.

Okay. Thank you so much, all of you, for your time and attention today, and we hope everyone is staying safe. And we also thank you for your continued interest in Glaukos. Goodbye.

And that does conclude today's conference. Again, thank you for your participation. You may now disconnect.